Invenomic Capital Management LP Has $15.53 Million Stake in IQVIA Holdings Inc. $IQV

Key Points

• Invenomic Capital Management LP significantly increased its stake in IQVIA Holdings Inc. by 65.7%, bringing its total to $15.53 million with ownership of 88,062 shares.
• Analysts have raised their price targets for IQVIA, with Mizuho setting a new target at $225, while a consensus rating of "Moderate Buy" has been affirmed among seventeen investment analysts.
• IQVIA's recent earnings report showed an EPS of $2.81, exceeding expectations, with a revenue of $4.02 billion, reflecting a 5.3% increase year-over-year.

Invenomic Capital Management LP raised its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 65.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 88,062 shares of the medical research company's stock after purchasing an additional 34,913 shares during the period. Invenomic Capital Management LP owned 0.05% of IQVIA worth $15,525,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Continuum Advisory LLC increased its holdings in shares of IQVIA by 3.7% in the fourth quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock valued at $354,000 after purchasing an additional 64 shares during the last quarter. Ballentine Partners LLC increased its holdings in shares of IQVIA by 4.9% in the first quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock valued at $260,000 after purchasing an additional 69 shares during the last quarter. Independent Advisor Alliance grew its stake in shares of IQVIA by 4.2% in the first quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company's stock valued at $318,000 after acquiring an additional 72 shares in the last quarter. ST Germain D J Co. Inc. grew its stake in shares of IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after acquiring an additional 76 shares in the last quarter. Finally, Nemes Rush Group LLC grew its stake in shares of IQVIA by 15.0% in the first quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company's stock valued at $109,000 after acquiring an additional 81 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Mizuho upped their price target on shares of IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a research note on Friday, July 25th. Barclays upped their price target on shares of IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 23rd. William Blair restated an "outperform" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Redburn Partners set a $214.00 target price on shares of IQVIA in a report on Wednesday. Finally, Cowen reissued a "buy" rating on shares of IQVIA in a report on Wednesday, July 23rd. Seventeen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $229.86.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 5,800 shares of the stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares in the company, valued at $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the transaction, the insider directly owned 2,910 shares in the company, valued at $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company's stock.

IQVIA Stock Down 0.2%

Shares of NYSE IQV opened at $184.24 on Friday. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $249.54. The company has a 50 day simple moving average of $179.28 and a 200 day simple moving average of $167.65. The firm has a market cap of $31.32 billion, a PE ratio of 26.66, a price-to-earnings-growth ratio of 2.03 and a beta of 1.32.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same quarter in the prior year, the business posted $2.64 EPS. The firm's revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.